LPL Financial’s Quince Therapeutics QNCX Stock Holding History

LPL Financial’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55	Closed	-$1.11K	–	6331
2026 Q1	$1.11K	Buy	+55	New	+$11K	﹤0.01%	5960

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial's QNCX Position: Q2 2026 in Review

LPL Financial sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 55 shares — an estimated $1.11K sold.

LPL Financial first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $1.11K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

LPL Financial reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
LPL Financial sold 55 Quince Therapeutics shares in Q2 2026, an estimated $1.11K.
LPL Financial first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
LPL Financial's Quince Therapeutics position peaked at $1.11K in Q1 2026.
27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.